Multifunction superpills could drastically reduce heart disease

10/9/2003 | Bloomberg Businessweek

Pfizer may be the first company to introduce a "superpill," one that combines its hypertension drug Norvasc and its cholesterol-lowering agent Lipitor. Merck will follow with a combination of Zocol and Zetia, while Bristol-Myers Squibb is developing a single-pill version of aspirin and Pravachol, its statin drug. These superpills could result in significant declines in heart disease, British researchers say.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI